Fine Foods & Pharmaceuticals N.T.M. SpA (FF) AI Stock Analysis

• Market Cap: €233.67M
• Dividend Yield: 1.46%
• Average Volume (3M): 32.10K
• Price to Earnings (P/E): 18.7
• Beta (1Y): 0.31
• Revenue Growth: 5.31%
• EPS Growth: 158.17%
• Country: IT
• Employees: 779
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 0.09
• Shares Outstanding: 22,060,125
• 10 Day Avg. Volume: 34,206
• 30 Day Avg. Volume: 32,102
• PEG Ratio: -0.07
• Price to Book (P/B): 1.45
• Price to Sales (P/S): 0.79
• P/FCF Ratio: 17.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €12.80
• Price Target Upside: 43.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.55
• Revenue Forecast (FY): €255.41M

• Rating: 73 Outperform
• Price Target: €9.50 ▲(6.74% Upside)

Fine Foods & Pharmaceuticals N.T.M. SpA's stock score is driven by strong technical indicators and solid financial performance, despite challenges in cash flow management. The valuation is moderate, suggesting potential for growth if financial improvements continue.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for the company's products and effective market strategies, supporting long-term business expansion.

Leverage Management

Improved leverage management enhances financial stability and reduces risk, allowing for more flexibility in future investments and operations.

Profit Margin Improvement

Enhanced profit margins reflect operational efficiency and cost control, which can lead to sustained profitability and competitive advantage.

Negative Factors

Cash Flow Challenges

Challenges in free cash flow generation can limit the company's ability to invest in growth opportunities and meet financial obligations, impacting long-term liquidity.

Free Cash Flow Conversion

Negative free cash flow conversion indicates inefficiencies in turning profits into cash, which may hinder the company's ability to fund operations and growth.

Equity Financing

A moderate equity financing level may limit financial resilience, suggesting the need for strengthened equity to support future growth and stability.

Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model

Company Description

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) is a leading company operating in the food and pharmaceutical sectors, specializing in the production and distribution of high-quality food ingredients, dietary supplements, and pharmaceutical excipients. The company focuses on innovation and sustainability, offering a diverse range of products that cater to the needs of both the food industry and healthcare markets. With a commitment to quality and safety, FF serves a global clientele, ensuring that its products meet stringent regulatory standards.

How the Company Makes Money

Fine Foods & Pharmaceuticals N.T.M. SpA generates revenue primarily through the sale of its core products, including food ingredients and pharmaceutical excipients. The company employs a multi-channel distribution model, supplying its products to manufacturers in the food and pharmaceutical industries. Key revenue streams include direct sales to businesses, partnerships with distributors, and collaborations with research institutions for the development of new products. Additionally, FF may benefit from contracts with large-scale clients and participation in international markets, which contribute to its earnings. Strategic partnerships with other companies in the supply chain also enhance its market reach and profitability.

Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview

Summary

Fine Foods & Pharmaceuticals N.T.M. SpA is showing signs of recovery with improved profitability and leverage metrics. The income statement reflects positive growth and margin improvements, while the balance sheet indicates better debt management. However, cash flow challenges persist, particularly with negative free cash flow, which could impact future investments and operational flexibility.

Income Statement

Fine Foods & Pharmaceuticals N.T.M. SpA has shown a consistent improvement in its gross profit margin, rising from 25.9% in 2022 to 38.9% in TTM 2025. The net profit margin has also improved to 3.9% in TTM 2025 from negative margins in previous years. Revenue growth is positive at 3.5% in TTM 2025, indicating a recovery from past declines. However, the EBIT and EBITDA margins, while improved, remain moderate, suggesting room for operational efficiency gains.

Balance Sheet

The company's debt-to-equity ratio has improved significantly from 0.90 in 2022 to 0.41 in TTM 2025, indicating better leverage management. Return on equity has also turned positive at 7.2% in TTM 2025, reflecting improved profitability. However, the equity ratio is not explicitly provided, and the company's total assets have decreased over the years, which could indicate potential risks in asset management.

Cash Flow

Operating cash flow remains strong, but free cash flow has been negative in recent periods, with a significant decline in TTM 2025. The free cash flow to net income ratio is positive, but the negative free cash flow growth rate of -281.7% in TTM 2025 is concerning. This suggests potential challenges in generating cash from operations and managing capital expenditures effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	256.43M	243.75M	251.81M	206.85M	194.42M	173.03M
Gross Profit	113.06M	80.13M	68.56M	53.63M	55.89M	49.23M
EBITDA	35.49M	30.90M	19.29M	3.64M	9.86M	28.80M
Net Income	12.52M	8.16M	-3.52M	-9.50M	-1.43M	13.36M
Balance Sheet
Total Assets	261.73M	242.59M	241.56M	299.82M	302.81M	207.44M
Cash, Cash Equivalents and Short-Term Investments	17.40M	19.21M	19.15M	76.74M	95.09M	74.95M
Total Debt	67.46M	54.53M	66.39M	120.36M	110.76M	21.19M
Total Liabilities	123.98M	110.53M	114.61M	166.53M	155.59M	66.43M
Stockholders Equity	137.75M	132.06M	126.95M	133.29M	147.22M	141.01M
Cash Flow
Free Cash Flow	306.45K	11.12M	-329.75K	-12.30M	-21.75M	14.66M
Operating Cash Flow	38.85M	45.85M	18.54M	3.69M	-5.83M	30.47M
Investing Cash Flow	-35.82M	-31.56M	45.89M	-15.31M	-36.35M	-12.34M
Financing Cash Flow	5.31M	-14.08M	-55.66M	4.74M	55.95M	-17.41M

Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Positive. The current price of 8.9 is below the 20-day moving average (MA) of 9.51, below the 50-day MA of 9.33, and above the 200-day MA of 8.20, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 54.11 is Neutral, neither overbought nor oversold. The STOCH value of 46.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:FF.

Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FF	73 Outperform	€233.67M	18.68	―	1.46%	5.31%	158.17%
VLS	66 Neutral	€112.08M	13.29	9.54%	3.65%	2.66%	9.72%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%